Stefanie Alzate

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

M. Amiot, R. Vij, B. Pégourié, 2017, Blood.

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

M. Amiot, R. Vij, B. Pégourié, 2016 .

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

R. Vij, B. Pégourié, Shaji K. Kumar, 2017 .

Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

M. Amiot, R. Vij, Shaji K. Kumar, 2015 .

Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).

M. Amiot, R. Vij, Shaji K. Kumar, 2015 .

Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.

M. Amiot, R. Vij, B. Pégourié, 2016 .